An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00109057
Recruitment Status : Completed
First Posted : April 25, 2005
Last Update Posted : June 21, 2013
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF (Avastin) therapy in any Genentech-sponsored Phase I or Phase II cancer study and who did not show evidence of disease progression at completion of the parent study will be eligible for inclusion in this trial.

Condition or disease Intervention/treatment Phase
Cancer Drug: Avastin (bevacizumab) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter Extension Study of Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab) in Subjects Treated With rhuMAb VEGF in a Previous Genentech-Sponsored Phase I or Phase II Cancer Study
Study Start Date : February 1998
Actual Study Completion Date : February 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previous participation in and completion of a Genentech-sponsored rhuMAb VEGF Phase I or Phase II cancer study
  • No evidence of progressive disease at completion of the parent study
  • For women of childbearing potential, use of an effective means of contraception
  • Signed informed consent

Exclusion Criteria:

  • Any unresolved or irreversible rhuMAb VEGF-related ongoing serious adverse events occurring during the parent study
  • Any history of central nervous system disease (e.g., primary brain tumor or seizures within 12 months of the first infusion on this study), and/or any evidence of brain metastases
  • Compromised renal or hepatic function, as defined in the parent protocol
  • Anemia, neutropenia, or thrombocytopenia, as defined in the parent protocol
  • Pregnancy (positive pregnancy test) or lactation
  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored rhuMAb VEGF cancer study
  • Recent (within 3 weeks of the first infusion of this study) major surgical procedure, biopsy of a parenchymal organ, or significant traumatic injury
  • Clinically significant cardiovascular disease (e.g., uncontrolled hypertension [blood pressure of >160/110 mmHg on medication], myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac dysrhythmia requiring medication, or peripheral vascular disease (Grade II or greater)
  • Serious, nonhealing wound, ulcer, or bone fracture
  • Current or recent (within 10 days of the first infusion on this study) use of oral or parenteral anticoagulants or aspirin (except as required to maintain patency of permanent indwelling intravenous [IV] catheters)
  • Inability to comply with study and/or follow-up procedures
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications

Responsible Party: Genentech, Inc. Identifier: NCT00109057     History of Changes
Other Study ID Numbers: AVF0778g
First Posted: April 25, 2005    Key Record Dates
Last Update Posted: June 21, 2013
Last Verified: June 2013

Keywords provided by Genentech, Inc.:
Advanced malignancies

Additional relevant MeSH terms:
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents